DGAP-News

Carl Zeiss Meditec AG: Carl Zeiss Meditec AG records revenue growth of 8.6 percent

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Quarterly / Interim
Statement/Half Year Results
Carl Zeiss Meditec AG: Carl Zeiss Meditec AG records revenue growth of 8.6
percent

11.05.2016 / 07:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Carl Zeiss Meditec AG records revenue growth of 8.6 percent

Earnings per share and EBIT increase/forecast for fiscal year specified in
more detail


JENA, 11 May 2016
Medical technology company Carl Zeiss Meditec AG increased its revenue by
8.6 percent in the first six months of the fiscal year, to EUR 540.8
million; earnings before interest and taxes (EBIT) also increased to EUR 75
million (prior year: EUR 61 million), corresponding to an EBIT margin of
13.9 percent (prior year: 12.2 percent). There were also favorable
measurement effects relating to currency hedges at the end of the reporting
period, which caused earnings per share (EPS) to climb to EUR 0.59 (prior
year: EUR 0.37).

The positive revenue trend was once again boosted by currency effects.
Assuming constant exchange rates, growth of 5.3 percent would have been
achieved. The positive development of earnings is attributable, equally, to
a favorable product mix and strict cost management.

All three strategic business units (SBUs) grew in the reporting period,
with ophthalmology making the strongest contributions to growth.

Revenue of the Ophthalmic Systems SBU increased by 11.1 percent to EUR
203.6 million (prior year: EUR 183.2 million). Diagnostic products and
refractive lasers both contributed to this increase. Revenue development
benefited from positive currency effects. Adjusted for currency effects,
revenue increased by 6.8 percent.

The Surgical Ophthalmology SBU achieved a revenue increase of 8.7 percent,
to EUR 188.1 million (previous year: EUR 173.0 million) - adjusted for
currency effects, revenue increased by 6.6 percent.

The Microsurgery SBU generated revenue of EUR 149.1 million, corresponding
to an increase of 5.2 percent compared with the prior year (EUR 141.7
million). After adjustment for currency effects, this would equate to
growth of 1.8 percent.

Dr Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, gave his take
on the 6-month figures: "The encouraging development of business confirms
our strategy. We optimize the clinical benefit of our products without
losing sight of the economic aspects of our customers."

Asia drives growth in the regions

EMEA (Europe, Middle East and Africa): Revenue in the EMEA region increased
by 3.7 percent, to EUR 177.7 million (prior year: EUR 171.3 million). As in